Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
Bayer HealthCare Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc., are committed to helping your patients access Nexavar therapy.
Nexavar is available through a network of select specialty pharmacy providers (SPPs)—offering coordinated, comprehensive support unique to this distribution model.
Learn more about our SPPs.
Nexavar is covered by a broad range of private insurance plans and is on formulary with most Medicare Part D plans. Support for Nexavar includes patient education, charitable organizations, local and state programs, and support groups. Patients with commercial insurance may also be eligible for co-pay assistance through REACH—helping limit the cost of Nexavar to no more than $100 per prescription.
Call 1.866.NEXAVAR (1.866.639.2827) to access this program, or learn more.